BioCentury | Mar 9, 2020
Finance

GenFleet eyes proof of concept with $50M series B

Looking to start its first international and proof-of-concept trials, GenFleet raised more than $50 million in a series B round led by CDH and Shenzhen Capital group. The round saw participation by new investors South...
BioCentury | Jan 30, 2020
Company News

Lilly culls most of its clinical immuno-oncology pipeline

Eli Lilly disclosed the pharma has discontinued development of four immuno-oncology programs on Thursday -- including one that cost $1.6 billion to acquire -- as part of its 4Q19 earnings update. The moves leave Eli...
BioCentury | Jul 11, 2019
Targets & Mechanisms

The tumor stroma rises as the newest source of immuno-oncology targets

With a spate of therapies entering the clinic, the next frontier in the fight against resistance to checkpoint inhibitors will be the stroma. The lead target marks a resurgence of interest in TGFβ, and behind...
BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
BioCentury | Apr 22, 2019
Distillery Therapeutics

TGFBR1 inhibition for GATA4-deficient lung cancer

DISEASE CATEGORY: Cancer INDICATION: Non-small cell lung cancer (NSCLC) Cell culture and mouse studies suggest inhibiting TGFBR1 could help treat GATA4-deficient NSCLC. In a human GATA4-deficient NSCLC cell line, a tool compound TGFBR1 inhibitor decreased...
BioCentury | Apr 10, 2019
Tools & Techniques

Microbiome makes its mark outside the gut

Microbiome makes its mark outside the gut The gut microbiome wasn’t the only population of bacteria under the spotlight at this year’s American Association for Cancer Research (AACR) meeting. A growing focus was on the...
BioCentury | Jan 17, 2019
Emerging Company Profile

Zelluna’s solid TCR plans

...large portfolio of TCRs against antigens that are critical to tumor survival: TERT, KRAS and TGFBR2...
...patients who had survived as long as 10 years after immunization with TERT, KRAS or TGFBR2...
...their TCRs. Zelluna’s second product, ZI-T01, is based on class I-restricted TCRs and targets a TGFBR2...
BioCentury | Dec 7, 2018
Financial News

After Ally Bridge-backed series A, Shanghai's GenFleet looks to clinic

With eight preclinical candidates and an experienced management team, immunology company GenFleet Therapeutics Co. Ltd. (Shanghai, China) raised RMB120 million ($17.4 million) in an untranched series A round to bring its first therapy into clinic...
BioCentury | Dec 6, 2018
Financial News

After Ally Bridge-backed series A, Shanghai's GenFleet looks to clinic

With eight preclinical candidates and an experienced management team, immunology company GenFleet Therapeutics Co. Ltd. (Shanghai, China) raised RMB120 million ($17.4 million) in an untranched series A round to bring its first therapy into clinic...
BioCentury | Aug 23, 2018
Distillery Therapeutics

Hepatic

INDICATION: Liver disease; drug-induced liver toxicity (DILI) Mouse studies suggest inhibiting TGFBR1 could help treat liver disease and DILI. In mouse models of chemical-induced chronic and acute liver injury, hepatocyte-specific knockout of TGFBR1 or a...
Items per page:
1 - 10 of 71